Clinical trials: Abuse, Drug
Genetic Underpinning of Substance Abuse, Polymorphism-genetic
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans
Background: Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction.
- Conditions
- Genetic Underpinning of Substance Abuse, Polymorphism-genetic, Drug Abuse/Dependence, Opiod-Related Disorders
- Trial name
- NCT02225184
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Substance-Related Disorders
Abuse Liability of Controlled-Release Oxycodone Formulations
The objective of this study is to examine the abuse liability of a single 40mg dose of 2 controlled release oxycodone formulations (Apo-Oxycodone CR® and OxyNEO®) in non-dependent recreational opioid users by assessing the…
- Trial name
- NCT02101840
- Testing
- Apo-Oxycodone CR®, OxyNEO®
- Where
- Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Pain, Acute Pain
A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused
The purpose of this clinical study was to evaluate whether healthy adults, who sometimes take drugs for pleasure, are likely to abuse GRT0151Y. This abuse potential is assessed at three different doses of GRT0151Y.
- Trial name
- NCT03768024
- Testing
- GRT0151Y 50 mg capsule, Hydromorphone IR 4 mg
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH